Business Context and Reporting Period
This Form 8-K Current Report was filed by Bionano Genomics, Inc. on August 23, 2018. The filing documents corporate governance amendments executed in connection with the closing of the Company's initial public offering (IPO) of units.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and governance changes rather than financial performance.
Material Changes
On August 23, 2018, the Company filed an Amended and Restated Certificate of Incorporation and adopted Amended and Restated Bylaws. Key changes include:
- Authorization of 200,000,000 shares of common stock.
- Elimination of all references to previously existing series of preferred stock.
- Authorization of 10,000,000 shares of undesignated preferred stock.
- Implementation of a staggered board structure with three classes of directors serving three-year terms.
- Requirement that directors may only be removed with cause and by a two-thirds vote of outstanding shares.
- Elimination of the ability for stockholders to take action by written consent.
- Restriction of the ability to call special stockholder meetings to the Board, the Chairman, or the CEO.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It does not disclose specific risks or contingencies beyond the standard incorporation of the full text of the Amended Certificate and Bylaws as exhibits.
Key Facts for Investor Verification
- Confirm the effective date of the IPO closing relative to the filing date.
- Verify the total authorized share count (200 million common, 10 million preferred).
- Review the specific provisions regarding director removal and special meeting calls in the attached exhibits.
- Note the elimination of written consent actions by stockholders.